Public Comments
Comments provided on: January 17, 2019
Comments provided to: U.S. Department of Health and Human Services (HHS), Washington, DC,
Resource Type: Public Comments
Current and Ongoing Data Transparency Activities in the Pharmaceutical Industry
Public Comments
Comments provided on: October 1, 2014
Comments provided to: Standing Senate Committee on Social Affairs, Science and Technology, Canada
Submission of comments on Draft proposal for an addendum, on transparency, to the ‘Functional specifications for the EU portal and EU database to be audited’
Public Comments
Comments provided on: February 18, 2015
Comments provided to: European Medicines Agency, United Kingdom
“Proposed Rule – Clinical Trial Registration and Results Submission” Comments to NIH
Public Comments
Comments provided on: March 20, 2015
Comments provided to: National Institutes of Health
Health Research Authority – Guidance on participant information at the end of a study
Public Comments
Comments provided on: October 3, 2014
Comments provided to: Health Research Authority, UK
Summary of Clinical Trial Results for Laypersons – Comments to European Medicines Agency
Public Comments
Comments provided on: August 16, 2016
Comments provided to: European Medicines Agency, UK
Comments on Healthy People 2030 Updated Health Literacy Definition
Public Comment
Comments provided on: August 5, 2019
Comments provided to: Secretary of Health and Human Services, Washington, DC
Enhancing the Diversity of Clinical Trial Populations – Comments to FDA
Public Comments
Comments provided on: July 30, 2019
Comments provided to: Food and Drug Administration
Ethical Considerations for Clinical Investigations of Medical Products involving Children: Guidance for Industry, Sponsors, and IRBs
Public Comment
Comments provided on: December 20, 2022
Comments provided to: Food and Drug Administration re: Docket No. FDA-2022-D-0738
Investigational New Drug Application Annual Reporting; A Proposed Rule
Public Comments / Sponsor Resource
Comments provided on: March 8, 2023
Comments provided to: Food and Drug Administration re: Docket No. FDA-2020-N-0258